ICO6 Rec'd PCT/PTO 08 APR 2005

U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE FORM PTO-1390 (Modified) (REV. 12-2004) 270423US0XPCT TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PCT/FR03/02964 8 October 2003 8 October 2002 TITLE OF INVENTION RECOMBINANT ADENOVIRAL VECTORS AND APPLICATIONS THEREOF APPLICANT(S) FOR DO/EO/US Marc ELOIT et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:  $\boxtimes$ This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.  $\boxtimes$ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.  $\boxtimes$ The US has been elected (Article 31). 4. 5.  $\boxtimes$ A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) a. 🗆 is attached hereto (required only if not communicated by the International Bureau). b. 🛛 has been communicated by the International Bureau. c. 🗆 is not required, as the application was filed in the United States Receiving Office (RO/US).  $\boxtimes$ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). 6. a. 🛛 is attached hereto. b. 🔲 has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) are attached hereto (required only if not communicated by the International Bureau). b. 🗆 have been communicated by the International Bureau. c. 🗆 have not been made; however, the time limit for making such amendments has NOT expired.  $\boxtimes$ have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 8. 9. П An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 11. A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. A copy of the International Search Report (PCT/ISA/210). Items 13 to 23 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. A FIRST preliminary amendment. 16. A SECOND or SUBSEQUENT preliminary amendment. 17. A substitute specification. 18. A power of attorney and/or change of address letter. 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 20. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 21. A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). 22. Express Mail Label No.  $\boxtimes$ 23. Other items or information: **Application Data Sheet Notice of Priority** Drawings (7 sheets) Sequence Listing (4 pages) Request for Consideration PCT/IB/304 PCT/IB/308

## JCO6 Rec'd PCT/PTO 08 APR 2005

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007, OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

THE ADDITIONAL OF FRANCE COST OF A STATE OF THE STATE OF								
U.S. APPLICATION NO (if known, see 37 CFR 1.5)			INTERNATIONAL APPLICATION NO. PCT/FR03/02964			ATTORNEY'S DOCKET NUMBER  270423US0XPCT		
24. The following fees are submitted:					904	Ann	licant use	Office use
a) Basic national fee						\$	\$300.00	Office use
							\$200.00	
⊠ c) Search fee\$400.00						\$	\$400.00	
TOTAL OF ABOVE CALCULATIONS = \$900.00							\$900.00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.								
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole						
- 100 =	/50 =				× \$250.00	\$	. \$0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).							\$130.00	
CLAIMS	NUMBER FILED N		UMBER EXTRA		RATE		•	
Total claims	29	- 20 =	9	x	\$50.00	\$	\$450.00	
Independent clair	ns 2	- 3=	0	x	\$200.00	\$	\$0.00	
MULTIPLE DEPE	NDENT CLAIMS	(if applicable)	⊠	+	\$360.00	\$	\$360.00	
TOTAL OF ABOVE CALCULATIONS =							\$1,840.00	
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.							\$0.00	
SUBTOTAL =						\$	\$1,840.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).							\$0.00	9
TOTAL NATIONAL FEE =							\$1,840.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +							\$0.00	
TOTAL FEES ENCLOSED =							\$1,840.00	
Amount to be refunded:								\$
Amount to be charged:								\$
a. A check in the amount of \$ to cover the above fees is enclosed.								
b. Please charge my Deposit Account No in the amount of to cover the above fee. A duplicate copy of this sheet is								
c.  The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No15-0030 A duplicate copy of this sheet is enclosed.								
d.   Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.								
SEND ALL CORRESPONDENCE TO:							vde Souch	<b>~</b>
Customer Number SIGNATURI						<u> </u>		
22850 Surinder Sachar Norman F						. Oblon		
Registration No. 34,423								
24,618								
REGISTRAT							IUMBER	



JC06 Rec'd PCT 0 08 APR 2005

DOCKET NO.: 270423US0XPCT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Marc ELOIT, et al. SERIAL NO.: NEW U.S. PCT APPLICATION

FILED: HEREWITH

INTERNATIONAL APPLICATION NO.: PCT/FR03/02964

INTERNATIONAL FILING DATE: October 8, 2003

FOR: RECOMBINANT ADENOVIRAL VECTORS AND APPLICATIONS THEREOF

## **REQUEST FOR PRIORITY UNDER 35 U.S.C. 119** AND THE INTERNATIONAL CONVENTION

Commissioner for Patents Alexandria, Virginia 22313

Sir:

In the matter of the above-identified application for patent, notice is hereby given that the applicant claims as priority:

COUNTRY

France

APPLICATION NO

DAY/MONTH/YEAR

08 October 2002

Certified copies of the corresponding Convention application(s) were submitted to the International Bureau in PCT Application No. PCT/FR03/02964. Receipt of the certified copy(s) by the International Bureau in a timely manner under PCT Rule 17.1(a) has been acknowledged as evidenced by the attached PCT/IB/304.

> Respectfully submitted, OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Attorney of Record

Registration No. 24,618

Surinder Sachar

Registration No. 34,423

Customer Number 22850

(703) 413-3000 Fax No. (703) 413-2220 (OSMMN 08/03)